Physician profile
James M Orrell
NPI 1447220900
$2,609.41
in general payments reported to CMS, 2019-2025
20 companies · $584 in 2025
The $584 reported for 2025 was more than what 86% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.16 · 2020: $26.82 · 2021: $554 · 2022: $726 · 2023: $274 · 2024: $420 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.87 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $776.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $229.92 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $207.05 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $106.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $78.32 | 2024 | Voquezna |
| Boston Scientific Corporation | $69.04 | 2023 | |
| Amgen INC. | $67.16 | 2022 | |
| Glaxosmithkline, LLC. | $39.71 | 2019-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $35.12 | 2023 | Cologuard Collection Kit |
| Alkermes, INC. | $32.76 | 2023 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $31.34 | 2024 | |
| Lilly USA, LLC | $21.71 | 2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $18.49 | 2025 | Injectafer |
| Astellas Pharma US INC | $18.39 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.49 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $13.93 | 2025 | Korlym |
| Pfizer INC. | $13.58 | 2025 | |
| Allergan, INC. | $12.83 | 2020 | |
| Corium, LLC | $7.41 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Orrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.